Previous 10 |
Multiple important Phase 3 and Phase 2 data events anticipated during 2020/2021 Arcutis currently expects no impact to its previously disclosed clinical timelines due to COVID-19 Strong financial position with $249.3 million in cash, cash equivalents and marketable securities WESTLAKE...
Enrollment is underway in a Phase 1/2b clinical trial evaluating Arcutis Biotherapeutics ( ARQT -2.4% ) ARQ-252 in adult patients with eczema (atopic dermatitis) on their hands. More news on: Arcutis Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more...
ARQ-252 is a Potent Topical Small Molecule Inhibitor of JAK1 High Selectivity for JAK1 over JAK2 JAK Inhibition a Biologically Validated Target for Treatment of Hand Eczema WESTLAKE VILLAGE, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a l...
WESTLAKE VILLAGE, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-derma...
FDA requests study amendment to allow inclusion of children ages 2 to 11 years in the DERMIS-1 and DERMIS-2 trials Strong safety profile supported population expansion in pivotal Phase 3 trials Topical Roflumilast potential “Best in Class” topical PDE4 inhibitor Phase 3 t...
Assuming no COVID-19 cancellations, here is a list of noteworthy events during the week of March 15 - 21 for healthcare investors: More news on: Eton Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Arcutis Biotherapeutics, Inc., Healthcare stocks news, , Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
WESTLAKE VILLAGE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermat...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration...
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Company has been in communication with the U....
2024-06-16 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...